[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556244":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":40,"responsibleParty":55,"collaborators":37,"id":58,"slug":37,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":37,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":37,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":37,"overallStatus":43,"whyStopped":37,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Armed Forces Hospital, Pakistan","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"neonates with HIE receiving citicoline","EXPERIMENTAL","this arm will include neonates suffering from hypoxic ischemic encephalopathy and who will be given injection citicoline",[13],"Drug: Citicoline Sodium",{"label":15,"type":16,"description":17,"interventionNames":18},"neonates with HIE receiving placebo","PLACEBO_COMPARATOR","this arm will include neonates who will be suffering from HIE but will recieve rotuine care in NICU but will not receive injection citicoline",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Citicoline Sodium","one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth",[9,15],[26],"placebo",[28],{"name":29,"affiliation":30,"role":31},"arshad Khushdil, FCPS","PEMH","PRINCIPAL_INVESTIGATOR",[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"arshad Khushdil","CONTACT","03463300030",null,"drarshad104589@yahoo.com",{"name":34,"role":35,"phone":36,"phoneExt":37,"email":37},[41],{"facility":42,"status":43,"city":44,"state":37,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"MH","RECRUITING","Rawalpindi","68000","Pakistan",{"type":48,"coordinates":49},"Point",[50,51],73.0479,33.59733,{"lat":51,"lon":50},[54],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},{"type":31,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":37,"oldOrganization":37},"arshad khushdil","Doctor","100556244",false,"NCT06522581","Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy","Inclusion Criteria:\n\n1. all indoor newborn babies with HIE II and III\n2. who have not received therapeutic hypothermia\n\nExclusion Criteria:\n\n1. grade I HIE\n2. Babies on TH\n3. babies whose parents do not give consent for inclusion in study\n4. babies with major congential malformations -","ALL","1 Day","30 Days",{"count":67,"type":68},200,"ESTIMATED","INTERVENTIONAL",[71],"PHASE1","Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births.\n\nInfants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.",[74],"Hypoxic Ischemic Encephalopathy of Newborn","2024-08-12",{"date":77,"type":78},"2024-08-14","ACTUAL",{"date":80,"type":78},"2024-01-01",{"date":82,"type":68},"2025-01-01",{"name":5,"class":6},1]